{
}
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS has rated CARL ZEISS MEDITEC AG as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing carries risks, including the potential loss of capital, and expert investment advice is recommended.
UBS has rated CARL ZEISS MEDITEC AG as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing in securities carries risks, including the potential total loss of capital. No liability for the accuracy or completeness of the information is assumed.
Deutsche Bank has maintained a "Hold" rating on Carl Zeiss Meditec, lowering the price target from EUR 66.00 to EUR 55.00 due to anticipated declines in Q1 results. Analysts forecast an 8% drop in organic sales and a 25% decrease in EBITA, attributing these challenges to a weak market in China and reduced equipment sales in the U.S. and Europe. The company's performance in the first quarter is crucial for meeting full-year guidance, which suggests moderate sales growth and stable EBITA margins.
The global Keratoconus Treatment market, valued at US$ 0.5 billion in 2022, is projected to grow to US$ 0.6 billion by 2031, with a CAGR of 3.9% from 2024 to 2031. Key players include Sandoz International GmbH, HOYA, and Menicon Co., Ltd., focusing on various treatment options like corrective lenses and corneal surgeries. Recent developments highlight Menicon's launch of the ROSE K hard contact lens in China, tailored for keratoconus patients.
UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a price target of 65 euros, following disappointing fourth-quarter results. The company's operating profit forecast for 2025 is over 10% below market expectations, with management citing a weak economy and consumption pressures in China, which may negatively impact investor sentiment.
Carl Zeiss Meditec AG, a German technology and medical devices firm, specializes in solutions for diagnosing and treating ophthalmic diseases, as well as providing visualization tools for microsurgery. The company operates in two main sectors: ophthalmic devices, which includes intraocular lenses and medical lasers, and microsurgery, covering neurosurgery and otolaryngology. With production sites across Europe, the U.S., and Asia, it continues to innovate in the medical technology field.
UBS has maintained a "Neutral" rating for Carl Zeiss Meditec, setting a target price of 65 euros. Analyst Graham Doyle expresses skepticism about the medical technology sector, noting that his sales and earnings forecasts for 2025 fall below consensus estimates for 10 of the 17 stocks he covers.
UBS has maintained a 'Neutral' rating for Carl Zeiss Meditec, setting a target price of 65 euros. Analyst Graham Doyle expresses skepticism about the medical technology sector, noting that his sales and earnings forecasts for 2025 fall below consensus for 10 of the 17 stocks he covers.
UBS has maintained a 'Neutral' rating for Carl Zeiss Meditec, setting a price target of 65 euros. Analyst Graham Doyle expressed skepticism about the medical technology sector, noting that his sales and earnings forecasts for 2025 are below consensus for 10 of the 17 stocks he covers. As of the latest trading, Carl Zeiss Meditec shares are priced at 57.85 euros, reflecting a slight increase of 0.26%.
The German ophthalmic devices market is projected to grow at a CAGR of 5.34% from 2023 to 2033, driven by the rising prevalence of eye disorders and an aging population. Key segments include cataract treatments, which are expected to dominate due to high demand for advanced surgical solutions. Recent developments include Carl Zeiss Meditec AG's acquisition of D.O.R.C., enhancing its ophthalmic portfolio.
Carl Zeiss Meditec AG
Companies
ubs rates carl zeiss meditec ag as neutral investment option
08:52 17.02.2025
ubs rates carl zeiss meditec ag as neutral investment option
11:11 31.01.2025
Deutsche Bank lowers price target for Carl Zeiss Meditec amid weak outlook
15:50 22.01.2025
global keratoconus treatment market analysis growth outlook and key players
Bausch Health Companies Inc.
Menicon Co., Ltd.
Seed Co. Ltd.
Johnson & Johnson Services Inc.
The Cooper Companies, Inc.
Novartis AG
Hoya Corp
Carl Zeiss Meditec AG
FRA
ARG
ARE
CAN
SAU
USA
RUS
IND
AUS
GBR
BHR
ITA
OMN
KWT
BRA
QAT
COL
DEU
CHN
MEX
ISR
JPN
Show more
14:48 09.01.2025
UBS Maintains Neutral Rating for Carl Zeiss Meditec Amid Economic Concerns
18:57 13.12.2024
Carl Zeiss Meditec AG Focuses on Ophthalmic Devices and Microsurgery Solutions
10:38 11.12.2024
ubs maintains neutral rating for carl zeiss meditec with target price of 65 euros
11:31 26.11.2024
ubs maintains neutral rating for carl zeiss meditec with target at 65 euros
10:31 26.11.2024
ubs maintains neutral rating for carl zeiss meditec with target at 65 euros
10:31 26.11.2024
germany ophthalmic devices market forecast growth driven by aging population and technology
Euro
Carl Zeiss Meditec AG
Topcon Corporation
Metall Zug Ltd.
Alcon Inc.
Bausch & Lomb Corp
EssilorLuxottica Société anonyme
DEU
FRA
Show more
09:40 19.11.2024
Trending
Subcategory:
Corporate News
Stock Market Updates
Industry Trends
Banking Regulations
Retail and Consumer Goods
Startups & Entrepreneurship
Global Financial Events
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
European Securities and Markets Authority
Government Policies
CEO Changes
Financial Scams and Security
Private Equity Deals
Government Economic Policies
Domestic Politics
Central Bank Actions
Global Trade Developments
Workplace Trends
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People:
DEUTSCHE BANK AG
Barclays plc
Natwest
UBS AG
Berkshire Hathaway Inc.
MERCK KGaA
Lloyds Banking Group plc
Hsbc Holdings B.V.
HSBC Holdings plc
Rheinmetall AG
Banco Santander SA
Standard Chartered
Delivery Hero SE
Huawei Technologies CO. Ltd.
Wells Fargo & Company
ING Groep N.V.
Unicredit
adidas AG
Google Inc.
Dell Technologies Inc.
United States Dollar
Euro
British Pound Sterling
Indian Rupee
Swiss Franc
Hong Kong Dollar
Japanese Yen
South Korean Won
Chinese Yuan
Canadian Dollar
Saudi Riyal
Australian Dollar
Russian Ruble
South African Rand
Nicaraguan Córdoba
United Arab Emirates Dirham
Indonesian Rupiah
Qatari Riyal
Pakistani Rupee
Egyptian Pound
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.